Trial Profile

The Effects of Empagliflozin on Functional and Structural Arterial Wall Characteristics

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Empagliflozin/metformin; Metformin
Indications Type 1 diabetes mellitus
Focus Pharmacodynamics

Most Recent Events

16 Jun 2020 Results (n=40) assessing oxidative effects of empagliflozin (alone and in combination with metformin) in type 1 diabetes mellitus patients presented at the 80th Annual Scientific Sessions of the American Diabetes Association
07 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com